ArticleCancer medicine2020

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.

Sameer A Parikh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.